In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine
about
sameAs
Pathogenesis of human immunodeficiency virus infectionNovel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidineSelection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidineIncreased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive personsK65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenineIdentification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidineResistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptaseInfluence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosidesSpecific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitorsHuman immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analopol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivoResistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integraseGeneration and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitorResistance of clinical isolates of human immunodeficiency virus to antiretroviral agentsGeneration of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidineThe same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidineAnti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptaseIn vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosineThe nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitorsNovel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitroAn in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidineDicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase.Antiviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions.Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidineA novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidineGenotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapyTribute to Mark WainbergAnimal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors.The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase.Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimenOpportunistic infections and CD4+ T-lymphocytopenia without HIV infection: report of two cases.Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcriptionSelection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidineMutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine.Mutations at codon 184 in simian immunodeficiency virus reverse transcriptase confer resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidineSensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not.Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy.
P2860
Q24634681-9295C3C8-EAAD-4565-AA76-0724AD3BCE92Q28342653-BB168FBB-7724-459D-8B4F-E191210CBE0FQ28344137-AEE8E0DA-5B88-4B46-AB06-796C622FE024Q28363547-A6263051-918F-448F-A625-FF443F894DD5Q28367386-EF8C483A-A9C5-4706-A817-EF0E004D9008Q28367543-B72034C9-D107-40D7-9BFB-652B99603091Q28367547-45E1F34D-EFA9-4D4A-A7EB-43A1A7D8D3F4Q28367580-41D6A4B3-2B71-440D-A894-FAB1C4D8A875Q28368032-5C76C725-485E-4B9B-A1B3-228C5CD1084CQ28368045-136A23E5-A91B-43AA-8926-F9E82D7F80CAQ28368048-E101A4D7-DDA9-4298-B523-899C24E227ACQ28368842-E3FDC62E-6DE7-45E5-A0A9-7D166781A928Q28378387-BD1E9D2B-AE79-454D-8BC3-282307CCEC77Q28378547-DF87EDAB-AB75-45C9-AE6B-6BA45922C0F6Q28378611-44B02545-1208-47E1-8E76-DEE6C7B32112Q28378626-8847BE0F-B7E5-4706-8507-E10225DE29ADQ28378745-B2221A84-1F11-406D-BAB8-A9DD61CFF7E6Q28378965-9B441917-8471-4782-B1AD-B7BC746FEC1EQ28379139-50F7214F-6FB2-4F0C-B94E-1716B20D416FQ28379249-15B00A6A-97F8-4D01-9910-ED6FFE4A3501Q28379270-152F81F5-EF9D-465E-8C61-5D3D4C70E556Q28379316-507CE47D-D19D-4293-959F-A2CA4AD7FC3DQ33748925-D26A6B74-09F2-4AA9-B1A2-7F384CA80C53Q33749177-7016E6B5-1B88-4D8D-AB03-B09748DB0605Q33753465-9CD2462C-D8BB-404E-B363-DAB16C2AA45BQ33782477-1925EAE5-DA60-4B96-8508-D7F1141B217CQ33784635-9374A920-A502-4E51-9EF7-0ABB8EEF78A3Q33846297-3C9FC07E-AB58-432F-AECF-DBC561A19FF9Q33957283-C82B9C95-77EA-48F2-8166-84B79679EA07Q33976004-EE690238-AEEC-48E5-B2EF-7C89ECC0476FQ34110204-BD465F87-E05F-4585-8527-1370C254D5B2Q34668716-EC7D999A-19EC-465A-A67E-D4D24258125CQ34680647-2C2B8682-6F9F-407B-AC86-5B362A394C1EQ34706226-D72BFB39-EF9B-484C-8360-76502C038478Q35122784-8F87C441-CCA3-494C-97A7-B76A35A18993Q35123759-B86C1B2B-0FC2-4D60-844E-2C56C8055B23Q35126454-1C199E8C-F009-4FEE-812D-550DA952FDBFQ35139503-E6F889A9-1157-413B-8A51-5A648BF4DB0CQ35312562-AE24A1DD-AB31-4C7B-B96C-EAD70B8B518CQ35839770-8CB5E12D-9CD1-404A-B15A-17BF5E53BA74
P2860
In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine
description
1992 nî lūn-bûn
@nan
1992 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
In vitro selection of variants ...... idine and 2',3'-dideoxyinosine
@ast
In vitro selection of variants ...... idine and 2',3'-dideoxyinosine
@en
In vitro selection of variants ...... idine and 2',3'-dideoxyinosine
@nl
type
label
In vitro selection of variants ...... idine and 2',3'-dideoxyinosine
@ast
In vitro selection of variants ...... idine and 2',3'-dideoxyinosine
@en
In vitro selection of variants ...... idine and 2',3'-dideoxyinosine
@nl
prefLabel
In vitro selection of variants ...... idine and 2',3'-dideoxyinosine
@ast
In vitro selection of variants ...... idine and 2',3'-dideoxyinosine
@en
In vitro selection of variants ...... idine and 2',3'-dideoxyinosine
@nl
P2093
P2860
P1433
P1476
In vitro selection of variants ...... idine and 2',3'-dideoxyinosine
@en
P2093
P2860
P407
P577
1992-01-01T00:00:00Z